Notice of NIH Policy to All Applicants: Meeting rosters are provided for information purposes only. Applicant investigators and institutional officials must not communicate directly with study section members about an application before or after the review. Failure to observe this policy will create a serious breach of integrity in the peer review process, and may lead to actions outlined in <u>NOT-OD-22-044</u>, including removal of the application from immediate review.

THE ROSTER INCLUDES MEMBERS FROM MULTIPLE CSR SPECIAL EMPHASIS PANELS OF THIS IRG:

CHAIRPERSONS

ADEYEYE, MOJI C, PHD PROFESSOR & CHAIR DEPARTMENT OF BIOPHARMACEUTICAL SCIENCES COLLEGE OF PHARMACY ROOSEVELT UNIVERSITY SCHAUMBURG, IL 60173

PRIOR, FRED WILLIAM, PHD PROFESSOR DEPARTMENT OF BIOMEDICAL INFORMATICS UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES LITTLE ROCK, AR 72205

SHROOT, BRAHAM, PHD CHIEF EXECUTIVE OFFICER SIGNUM BIOSCIENCES, INC MONMOUTH JUNCTION, NJ 08852

MEMBERS

ALTON, GORDON, PHD PRESIDENT AND CHIEF EXECUTIVE OFFICER VISIONARY PHARMACEUTICALS, INC. SAN DIEGO, CA 92126

BARNGROVER, DEBRA, PHD SENIOR CONSULTANT BIOLOGICS CONSULTING GROUP ALEXANDRIA, VA 22314

BEATON, GRAHAM, PHD DIRECTOR OF CHEMISTRY EPIGEN BIOSCIENCES SAN DIEGO, CA 92121 CHAUHAN, ABHAY S, PHD DIRECTOR OF PHARMACEUTICAL NANOTECHNOLOGY DEPARTMENT OF PHARMACEUTICAL SCIENCES SCHOOL OF PHARMACY CONCORDIA UNIVERSITY WISCONSIN MEQUON, WI 53097

CHILCOTE, TAMIE, PHD CHIEF OPERATING OFFICER ACTIVESITE PHARMACEUTICALS, INC. BERKELEY, CA 94710

FOUTS, TIMOTHY R, PHD SENIOR DIRECTOR OF VIROLOGY PROFECTUS BIOSCIENCES, INC. BALTIMORE, MD 21224

HAM, ANTHONY S.W, PHD DIRECTOR OF FORMULATION DEPARTMENT OF FORMULATION IMQUEST BIOSCIENCES FREDERICK, MD 21704

HAWI, AMALE, PHD CONSULTANT PHARMACEUTICAL DEVELOPMENT PENWEST PHARMACEUTICALS, CO. RIDGEFIELD, CT 06877

HOWARD, JOHN A, PHD PRESIDENT APPLIED BIOTECHNOLOGY INSTITUTE CALIFORNIA POLYTECHNIC STATE UNIVERSITY SAN LUIS OBISPO, CA 93407

Notice of NIH Policy to All Applicants: Meeting rosters are provided for information purposes only. Applicant investigators and institutional officials must not communicate directly with study section members about an application before or after the review. Failure to observe this policy will create a serious breach of integrity in the peer review process, and may lead to actions outlined in <u>NOT-OD-22-044</u>, including removal of the application from immediate review.

IGNATOVICH, FILIPP, PHD CHIEF TECHNOLOGY OFFICER LUMETRICS, INC. ROCHESTER, NY 14623

KOCHUNOV, PETER V, PHD ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY MARYLAND PSYCHIATRIC RESEARCH CENTER UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE BALTIMORE, MD 21201

LANE, COURTNEY C, PHD VICE PRESDENT, CLINICAL AFFAIRS AXONICS MODULATION TECHNOLOGIES, INC IRVINE, CA 92618

LEBOVITZ, RUSSELL M, MD, PHD CEO DEPARTMENT OF SKINCENTIAL SCIENCES AMPRION, INC. HOUSTON, TX 77019

LOCHHEAD, MICHAEL J, PHD VICE PRESIDENT, CHIEF TECHNOLOGY OFFICER MBIO DIAGNOSTICS, INC. BOULDER, CO 80303

MARSHALL, ANDREW, PHD DIRECTOR AND CHIEF TECHNOLOGY OFFICER HEALIONICS CORPORATION SEATTLE, WA 98103

MCCHESNEY, DANIEL D, VICE PRESIDENT DECIBIO CONSULTING, LLC SANTA MONICA, CA 90401 MCLAUGHLIN, JEFFERY, EXECUTIVE DIRECTOR RADIANT CREATIVE GROUP 2200 NORTH LOOP WEST SUITE 114 HOUSTON, TX 77018

MURTHY, SATHYANARAYANA N, PHD ASSOCIATE PROFESSOR SCHOOL OF PHARMACY THE UNIVERSITY OF MISSISSIPPI UNIVERSITY, MS 38677

OHLSSON-WILHELM, BETSY M, PHD CHIEF EXECUTIVE OFFICER SCIGRO, INCORPORATED CAMBRIDGE, MA 02139

PARRY, TOM J, PHD SENIOR DIRECTOR PHARMACOLOGY AND SAFETY ACORDA THERAPEUTICS, INC. ARDSLEY, NY 10502

SANGHVI, NARENDRA T, PHD, PRESIDENT FOCUS SURGERY INC. INDIANAPOLIS, IN 46226

SCHUTZER, STEVEN E, MD PROFESSOR DEPARTMENT OF MEDICINE UMDNJ- NEW JERSEY MEDICAL SCHOOL NEWARK, NJ 07103

Page 2 04/24/2024

Notice of NIH Policy to All Applicants: Meeting rosters are provided for information purposes only. Applicant investigators and institutional officials must not communicate directly with study section members about an application before or after the review. Failure to observe this policy will create a serious breach of integrity in the peer review process, and may lead to actions outlined in NOT-OD-22-044, including removal of the application from immediate review.

SCHWIEBERT, ERIK M, PHD CHIEF EXECUTIVE OFFICER CHIEF SCIENTIFIC OFFICER AND DIRECTOR DISCOVERYBIOMED, INC. BIRMINGHAM, AL 35242

SLATTERY, WILLIAM H, MD CEO OF O-RAY PHARMA VICE PRESIDENT, HOUSE CLINIC UNIVERSITY OF CALIFORNIA LOS ANGELES, CA 91107

SMITH, ELIZABETH A, PHD PRINCIPAL SOMAX CONSULTING, LLC OLNEY, MD 28032

SOLIZ, PETER, PHD PRESIDENT AND CEO DEVELOPING INNOVATIVE DIAGNOSTIC TECHIQUES VISION QUEST BIOMEDICAL ALBUQUERQUE, NM 87106

SU, XIAOLI, PHD DIRECTOR OF RESEARCH AND DEVELOPMENT BIODETECTION INSTRUMENTS, INC. FAYETTEVILLE, AR 72701

TAN, HOCK S, PHD PRINCIPAL BIONEX PHARMACEUTICALS LLC EAST BRUNSWICK, NJ 08816

TURNER, JESSICA, PHD ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHOLOGY COLLEGE OF ARTS AND SCIENCES GEORGIA STATE UNIVERSITY ATLANTA, GA 30302 WANG, LEI, PHD ASSISTANT PROFESSOR DEPARTMENT OF PSYCHIATRY AND BEHAVIORAL SCIENCES FEINBERG SCHOOL OF MEDICINE NORTHWESTERN UNIVERSITY CHICAGO, IL 60614

WEISSMAN, ARTHUR D, PHD PRESIDENT VITROCELL PRECLINICAL SERVICES BALTIMORE, MD 21215

WILSON, BRUCE G, MBA BUSINESS MANAGER BARRON ASSOCIATES, INC. CHARLOTTESVILLE, VA 22901

WONG, STEPHEN TC, PHD PROFESSOR DEPARTMENT OF RADIOLOGY THE METHODIST HOSPITAL UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER HOUSTON, TX 77030

SCIENTIFIC REVIEW OFFICERS

BACKMAN, CRISTINA, PHD SCIENTIFIC REVIEW OFFICER CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH BETHESDA, MD 20892

BENNETT, YVONNE, PHD SCIENTIFIC REVIEW OFFICER CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH BETHESDA, MD 20892

Notice of NIH Policy to All Applicants: Meeting rosters are provided for information purposes only. Applicant investigators and institutional officials must not communicate directly with study section members about an application before or after the review. Failure to observe this policy will create a serious breach of integrity in the peer review process, and may lead to actions outlined in NOT-OD-22-044, including removal of the application from immediate review.

LOW, SHARON S, PHD SCIENTIFIC REVIEW OFFICER CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH BETHESDA, MD 20892

EXTRAMURAL SUPPORT

<u>ASSISTANTS</u> ALHARMOOSH, SYLVANA, LEAD AND DIVISION EXTRAMURAL SUPPORT SPECIALIST AND COORDINATOR CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH BETHESDA, MD 20892

COHEN, MELISSA A, EXTRAMURAL SUPPORT ASSISTANT CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH BETHESDA, MD 20892

TEYMOURIAN, SHEMA, EXTRAMURAL SUPPORT ASSISTANT CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH BETHESDA, MD 20892

UDDIN, ISHRAT, ADMINISTRATIVE ASSISTANT CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH BETHESDA, MD 20892

WAITERS, WYKENA B, EXTRAMURAL SUPPORT ASSISTANT CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH BETHESDA, MD 20814

Consultants are required to absent themselves from the room during the review of any application if their presence would constitute or appear to constitute a conflict of interest.

Committee Management AGGREGATE SEP ROSTER End of Report